Opinion

Austrian medicines authority positive towards biosimilar interchangeability

Published in: Volume 6 / Year 2017 / Issue 1
Author(s):
Page: 41

Abstract: Clinical evidence supporting biosimilar use is growing and for the first time, the Austrian Medicines and Medical Devices Agency takes a positive position on interchangeability. They now state that… Read More »

Where does the value of ‘value-added’ pharmaceuticals come from?

Published in: Volume 5 / Year 2016 / Issue 4
Author(s):
Page: 171-3

Abstract: The role of sound science, discovery, and innovation in value-added pharmaceuticals has not been sufficiently considered. This term is mainly used to define improved version of generic drugs. The… Read More »

Challenges of developing generics substitution policies in low- and middle-income countries (LMICs)

Published in: Volume 4 / Year 2015 / Issue 4
Author(s): ,
Page: 171-2

Abstract: There are few challenges to developing effective generics substitution policies in low- and middle-income countries (LMICs). These include the absence of generics substitution policies, lack of enforcement, lack of… Read More »

Is Australia positioned to take advantage of biosimilars?

Published in: Volume 3 / Year 2014 / Issue 4
Author(s):
Page: 184-7

Abstract: Australia currently has a small generic and biosimilar medicine industry despite having a good track record in biomedical research and a sound reputation in producing high quality but small… Read More »

Tell me the whole story: the role of product labelling in building user confidence in biosimilars in Europe

Published in: Volume 3 / Year 2014 / Issue 4
Author(s):
Page: 188-92

Abstract: The European Medicines Agency (EMA) has led the development of biosimilar regulatory pathways globally, tailoring their approach to meet the specific and scientifically determined needs of biosimilar development. However,… Read More »

Pathway to affordable, quality-assured sources of pegylated interferon alpha for treating hepatitis C

Published in: Volume 2 / Year 2013 / Issue 4
Author(s): ,
Page: 194-203

Author byline as per print journal: Barbara Milan, Sara Gaspani Introduction: The current pipeline of promising oral hepatitis C drugs could lead to a revolution in treatment for this disease… Read More »

Killing three birds with one stone: the satisfaction of healthcare –payers, patients and physicians with generic imatinib – mission NOT impossible!

Author(s): ,

Abstract: With the begining of the era of tyrosine kinase inhibitors (TKIs), chronic myeloid leukemia (CML) became a chronic disease, in which good-responding patients usually have a life expectancy similar… Read More »

Rationalizing FDA guidance on biosimilars—expediting approvals and acceptance

Author(s):

Abstract: Since the passage of H.R. 3590 Sec. 7002 in 2009, commonly known as the BPCIA, the FDA has licensed only nine products. The FDA has issued, several guidelines, as… Read More »

Go Back Print